174 related articles for article (PubMed ID: 19459652)
1. Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.
Sato N; Ando M; Ishikawa S; Jitsuoka M; Nagai K; Takahashi H; Sakuraba A; Tsuge H; Kitazawa H; Iwaasa H; Mashiko S; Gomori A; Moriya R; Fujino N; Ohe T; Ishihara A; Kanatani A; Fukami T
J Med Chem; 2009 May; 52(10):3385-96. PubMed ID: 19459652
[TBL] [Abstract][Full Text] [Related]
2. Discovery of pyridone-containing imidazolines as potent and selective inhibitors of neuropeptide Y Y5 receptor.
Ando M; Sato N; Nagase T; Nagai K; Ishikawa S; Takahashi H; Ohtake N; Ito J; Hirayama M; Mitobe Y; Iwaasa H; Gomori A; Matsushita H; Tadano K; Fujino N; Tanaka S; Ohe T; Ishihara A; Kanatani A; Fukami T
Bioorg Med Chem; 2009 Aug; 17(16):6106-22. PubMed ID: 19616955
[TBL] [Abstract][Full Text] [Related]
3. Discovery of novel orally active ureido NPY Y5 receptor antagonists.
Li G; Stamford AW; Huang Y; Cheng KC; Cook J; Farley C; Gao J; Ghibaudi L; Greenlee WJ; Guzzi M; van Heek M; Hwa JJ; Kelly J; Mullins D; Parker EM; Wainhaus S; Zhang X
Bioorg Med Chem Lett; 2008 Feb; 18(3):1146-50. PubMed ID: 18160282
[TBL] [Abstract][Full Text] [Related]
4. Synthesis, structure-activity relationship, and pharmacological studies of novel melanin-concentrating hormone receptor 1 antagonists 3-aminomethylquinolines: reducing human ether-a-go-go-related gene (hERG) associated liabilities.
Kasai S; Kamata M; Masada S; Kunitomo J; Kamaura M; Okawa T; Takami K; Ogino H; Nakano Y; Ashina S; Watanabe K; Kaisho T; Imai YN; Ryu S; Nakayama M; Nagisa Y; Takekawa S; Kato K; Murata T; Suzuki N; Ishihara Y
J Med Chem; 2012 May; 55(9):4336-51. PubMed ID: 22490048
[TBL] [Abstract][Full Text] [Related]
5. Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.
Takahashi T; Haga Y; Sakamoto T; Moriya M; Okamoto O; Nonoshita K; Shibata T; Suga T; Takahashi H; Hirohashi T; Sakuraba A; Gomori A; Iwaasa H; Ohe T; Ishihara A; Ishii Y; Kanatani A; Fukami T
Bioorg Med Chem Lett; 2009 Jul; 19(13):3511-6. PubMed ID: 19464889
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists.
Suzuki T; Kameda M; Ando M; Miyazoe H; Sekino E; Ito S; Masutani K; Kamijo K; Takezawa A; Moriya M; Ito M; Ito J; Nakase K; Matsushita H; Ishihara A; Takenaga N; Tokita S; Kanatani A; Sato N; Fukami T
Bioorg Med Chem Lett; 2009 Sep; 19(18):5339-45. PubMed ID: 19683441
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.
Torrens A; Mas J; Port A; Castrillo JA; Sanfeliu O; Guitart X; Dordal A; Romero G; Fisas MA; Sánchez E; Hernández E; Pérez P; Pérez R; Buschmann H
J Med Chem; 2005 Mar; 48(6):2080-92. PubMed ID: 15771450
[TBL] [Abstract][Full Text] [Related]
8. Optimization of a series of 2,4-diaminopyridines as neuropeptide Y Y1 receptor antagonists with reduced hERG activity.
Kameda M; Kobayashi K; Ito H; Miyazoe H; Tsujino T; Nakama C; Kawamoto H; Ando M; Ito S; Suzuki T; Kanno T; Tanaka T; Tahara Y; Tani T; Tanaka S; Tokita S; Sato N
Bioorg Med Chem Lett; 2009 Aug; 19(15):4325-9. PubMed ID: 19487123
[TBL] [Abstract][Full Text] [Related]
9. Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds.
Sakamoto T; Moriya M; Tsuge H; Takahashi T; Haga Y; Nonoshita K; Okamoto O; Takahashi H; Sakuraba A; Hirohashi T; Shibata T; Kanno T; Ito J; Iwaasa H; Gomori A; Ishihara A; Fukuroda T; Kanatani A; Fukami T
Bioorg Med Chem; 2009 Jul; 17(14):5015-26. PubMed ID: 19525116
[TBL] [Abstract][Full Text] [Related]
10. Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor.
Fichtner M; Lee E; Tomlinson E; Scott D; Cornelius P; Patterson TA; Carpino PA
Bioorg Med Chem Lett; 2012 Apr; 22(8):2738-43. PubMed ID: 22445286
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists.
Norman MH; Chen N; Chen Z; Fotsch C; Hale C; Han N; Hurt R; Jenkins T; Kincaid J; Liu L; Lu Y; Moreno O; Santora VJ; Sonnenberg JD; Karbon W
J Med Chem; 2000 Nov; 43(22):4288-312. PubMed ID: 11063624
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and evaluation of a novel cyclohexanamine class of neuropeptide Y Y1 receptor antagonists.
Cho K; Ando M; Kobayashi K; Miyazoe H; Tsujino T; Ito S; Suzuki T; Tanaka T; Tokita S; Sato N
Bioorg Med Chem Lett; 2009 Aug; 19(16):4781-5. PubMed ID: 19596193
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and evaluation of new arylsulfonamidomethylcyclohexyl derivatives as human neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
Moreno A; Pérez S; Galiano S; Juanenea L; Erviti O; Frígola C; Aldana I; Monge A
Eur J Med Chem; 2004 Jan; 39(1):49-58. PubMed ID: 14987833
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel benzimidazole derivative as a highly potent NPY Y5 receptor antagonist with an anti-obesity profile.
Tamura Y; Hayashi K; Omori N; Nishiura Y; Watanabe K; Tanaka N; Fujioka M; Kouyama N; Yukimasa A; Tanaka Y; Chiba T; Tanioka H; Nambu H; Yukioka H; Sato H; Okuno T
Bioorg Med Chem Lett; 2013 Jan; 23(1):90-5. PubMed ID: 23206862
[TBL] [Abstract][Full Text] [Related]
15. Analysis of van der Waals surface area properties for human ether-a-go-go-related gene blocking activity: computational study on structurally diverse compounds.
Moorthy NS; Ramos MJ; Fernandes PA
SAR QSAR Environ Res; 2012 Jul; 23(5-6):521-36. PubMed ID: 22452318
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and evaluation of 5,5-diphenylimidazolones as potent human neuropeptide Y5 receptor antagonists.
Gillman KW; Higgins MA; Poindexter GS; Browning M; Clarke WJ; Flowers S; Grace JE; Hogan JB; McGovern RT; Iben LG; Mattson GK; Ortiz A; Rassnick S; Russell JW; Antal-Zimanyi I
Bioorg Med Chem; 2006 Aug; 14(16):5517-26. PubMed ID: 16697206
[TBL] [Abstract][Full Text] [Related]
17. Hit to lead SAR study on benzoxazole derivatives for an NPY Y5 antagonist.
Omori N; Kouyama N; Yukimasa A; Watanabe K; Yokota Y; Tanioka H; Nambu H; Yukioka H; Sato N; Tanaka Y; Sekiguchi K; Okuno T
Bioorg Med Chem Lett; 2012 Mar; 22(5):2020-3. PubMed ID: 22300657
[TBL] [Abstract][Full Text] [Related]
18. Identification of a nonbasic melanin hormone receptor 1 antagonist as an antiobesity clinical candidate.
Washburn WN; Manfredi M; Devasthale P; Zhao G; Ahmad S; Hernandez A; Robl JA; Wang W; Mignone J; Wang Z; Ngu K; Pelleymounter MA; Longhi D; Zhao R; Wang B; Huang N; Flynn N; Azzara AV; Barrish JC; Rohrbach K; Devenny JJ; Rooney S; Thomas M; Glick S; Godonis HE; Harvey SJ; Cullen MJ; Zhang H; Caporuscio C; Stetsko P; Grubb M; Maxwell BD; Yang H; Apedo A; Gemzik B; Janovitz EB; Huang C; Zhang L; Freeden C; Murphy BJ
J Med Chem; 2014 Sep; 57(18):7509-22. PubMed ID: 25165888
[TBL] [Abstract][Full Text] [Related]
19. Potent, selective, and orally efficacious antagonists of melanin-concentrating hormone receptor 1.
Tavares FX; Al-Barazanji KA; Bigham EC; Bishop MJ; Britt CS; Carlton DL; Feldman PL; Goetz AS; Grizzle MK; Guo YC; Handlon AL; Hertzog DL; Ignar DM; Lang DG; Ott RJ; Peat AJ; Zhou HQ
J Med Chem; 2006 Nov; 49(24):7095-107. PubMed ID: 17125262
[TBL] [Abstract][Full Text] [Related]
20. Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist.
Haga Y; Sakamoto T; Shibata T; Nonoshita K; Ishikawa M; Suga T; Takahashi H; Takahashi T; Takahashi H; Ando M; Murai T; Gomori A; Oda Z; Kitazawa H; Mitobe Y; Kanesaka M; Ohe T; Iwaasa H; Ishii Y; Ishihara A; Kanatani A; Fukami T
Bioorg Med Chem; 2009 Oct; 17(19):6971-82. PubMed ID: 19720539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
